finafloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, nalidixic acid derivatives | 4920 | 209342-40-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Finafloxacin belongs to the fluoroquinolone class of antibacterials which involves the inhibition of bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Hosey CM, Chan R, Benet LZ |
| Vd (Volume of distribution) | 1.42 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.75 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.75 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 13.42 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.13 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 17, 2014 | FDA | ALCON RES LTD |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0023650 | Quinolones |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000892 | Anti-Infective Agents, Urinary |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| MeSH PA | D059003 | Topoisomerase Inhibitors |
| FDA EPC | N0000175937 | Quinolone Antimicrobial |
| CHEBI has role | CHEBI:33281 | antibiotics |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute otitis externa | indication | 30250000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.68 | acidic |
| pKa2 | 6.18 | Basic |
| pKa3 | 2.52 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.3% | XTORO | FONSECA BIOSCIENCES | N206307 | Dec. 17, 2014 | DISCN | SUSPENSION/DROPS | OTIC | 9119859 | July 2, 2030 | TREATMENT OF ACUTE OTITIS EXTERNA |
| 0.3% | XTORO | FONSECA BIOSCIENCES | N206307 | Dec. 17, 2014 | DISCN | SUSPENSION/DROPS | OTIC | 8536167 | Aug. 8, 2031 | TREATMENT OF ACUTE OTITIS EXTERNA |
| 0.3% | XTORO | FONSECA BIOSCIENCES | N206307 | Dec. 17, 2014 | DISCN | SUSPENSION/DROPS | OTIC | 9504691 | Nov. 21, 2033 | TREATMENT OF ACUTE OTITIS EXTERNA |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D26OSN9Q4R | UNII |
| D10575 | KEGG_DRUG |
| C2825286 | UMLSCUI |
| CHEBI:85176 | CHEBI |
| CHEMBL1908370 | ChEMBL_ID |
| 11567473 | PUBCHEM_CID |
| DB09047 | DRUGBANK_ID |
| 8121 | INN_ID |
| C560572 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10809 | IUPHAR_LIGAND_ID |
| 209342-41-6 | SECONDARY_CAS_RN |
| 1598641 | RXNORM |
| 708794002 | SNOMEDCT_US |
| 714690003 | SNOMEDCT_US |
Pharmaceutical products:
None